NT5E and asthma: Finally, the CD73 inhibitor APCP was administered to reduce inflammation and subcutaneous fibrosis.<h4>Conclusion</h4>Elevated adenosine metabolism plays an inflammatory role in asthma, and CD73 could be a potential therapeutic target for asthma.